MENU

Local

Sunday, May 19, 2024

Pfizer signs pact for hepatitis C study

November 18, 2010 11:00 pm • Last Updated: November 19, 2010 1:03 am

Pfizer Inc. and Exalenz Bioscience Ltd. have signed an agreement that will pay the Israeli diagnostic device maker $800,000 for helping study a mid-stage experimental drug for treating hepatitis C.

The trial is expected to start in December and last nine months. Exalenz will provide its BreathID devices to 10 medical centers in Asia to test liver function of trial participants.

According to Exalenz's website, the BreathID System can assess "a range of liver and gastrointestinal disorders via molecular analysis of the patient's exhaled breath."

According to Pfizer's pipeline report, its only hepatitis C drug in Phase 2 trials is filibuvir.

Comment threads are monitored for 48 hours after publication and then closed.

STORIES THAT MAY INTEREST YOU

Bankers honor Alves

Kate Alves of Groton, an assistant vice president at Chelsea Groton Bank, has been named a 2015 "New Leader in Banking" by The Connecticut Banker's Association. The award, bestowed last month at Moheg...

Court upholds Navy kickbacks term

A federal court of appeals has upheld the sentence of a former civilian Navy employee for orchestrating a long-running $18 million kickback scheme. The 1st U.S. Circuit Court of Appeals upheld the sen...

Harvard Pilgrim names Connecticut VP

Mark A. Jardin has been named Harvard Pilgrim Health Care's vice president for Connecticut. Formerly of Aetna, Jardin held many roles there, including managing director for the Middle East and Africa....

Uncasville student wins bank scholarship

XuJia "Jack" Cao of Uncasville has been selected as the 2014 recipient of the Donald B. Wilbur Scholarship, presented by the Liberty Bank Foundation. The $1,000 scholarship is presented annually to ...